Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial

A Multifunctional Contrast Agent for 19F-Based Magnetic Resonance Imaging

Magnetic resonance imaging, MRI, relying on ¹⁹F nuclei has attracted much attention, because the isotopes exhibit a high gyromagnetic ratio (comparable to that of protons) and have 100% natural abundance. Furthermore, due to the very low traces of intrinsic fluorine in biological tissues, fluorine labeling allows easy visualization in vivo using ¹⁹F-based MRI. However, one of the drawbacks of the available fluorine tracers is their very limited solubility in water. Here, we detail the design and preparation of a set of water-compatible fluorine-rich polymers as contrast agents that can enhance the effectiveness of ¹⁹F-based MRI. The agents are synthesized using the nucleophilic addition reaction between poly(isobutylene-alt-maleic anhydride) copolymer and a mixture of amine-appended fluorine groups and polyethylene glycol (PEG) blocks. This allows control over the polymer architecture and stoichiometry, resulting in good affinity to water solutions. We further investigate the effects of introducing additional segmental mobility to the fluorine moieties in the polymer, by inserting a PEG linker between the moieties and the polymer backbone. We find that controlling the polymer stoichiometry and introducing additional segmental mobility enhance the NMR signals and narrow the peak profile. In particular, we assess the impact of the PEG linker on T₂* and T₁ relaxation times, using a series of gradient-recalled echo images with varying echo times, TE, or recovery time, TR, respectively. We find that for equivalent concentrations, the PEG linker greatly increases T₂*, while maintaining high T₁ values, as compared to polymers without this linker. Phantom images collected from these compounds show bright signals over a background with high intensities.

Nanoparticles of gadolinium-incorporated Prussian blue with PEG coating as an effective oral MRI contrast agent for gastrointestinal tract imaging

Biocompatible nanoparticles of gadolinium-incorporated Prussian blue with the empirical formula K(0.94)Gd(0.02)Fe[Fe(CN)6] exhibit extremely high stability against the release of Gd(3+) and CN(-) ions under the acidic conditions similar to stomach juice. The high r1 relaxivity, low cytotoxicity and the ability of such nanoparticles to penetrate the cell membrane suggest that this coordination-polymer structural platform offers a unique opportunity for developing the next generation of T1-weighted oral cellular MRI probes for the early detection of tumors in the gastrointestinal tract.

Selected physicochemical aspects of poly- and perfluoroalkylated substances relevant to performance, environment and sustainability-part one

The elemental characteristics of the fluorine atom tell us that replacing an alkyl chain by a perfluoroalkyl or polyfluorinated chain in a molecule or polymer is consequential. A brief reminder about perfluoroalkyl chains, fluorocarbons and fluorosurfactants is provided. The outstanding, otherwise unattainable physicochemical properties and combinations thereof of poly and perfluoroalkyl substances (PFASs) are outlined, including extreme hydrophobic and lipophobic character; thermal and chemical stability in extreme conditions; remarkable aptitude to self-assemble into sturdy thin repellent protecting films; unique spreading, dispersing, emulsifying, anti-adhesive and levelling, dielectric, piezoelectric and optical properties, leading to numerous industrial and technical uses and consumer products. It was eventually discovered, however, that PFASs with seven or more carbon-long perfluoroalkyl chains had disseminated in air, water, soil and biota worldwide, are persistent in the environment and bioaccumulative in animals and humans, raising serious health and environmental concerns. Further use of long-chain PFASs is environmentally not sustainable. Most leading manufacturers have turned to shorter four to six carbon perfluoroalkyl chain products that are not considered bioaccumulative. However, many of the key performances of PFASs decrease sharply when fluorinated chains become shorter. Fluorosurfactants become less effective and less efficient, provide lesser barrier film stability, etc. On the other hand, they remain as persistent in the environment as their longer chain homologues. Surprisingly little data (with considerable discrepancies) is accessible on the physicochemical properties of the PFASs under examination, a situation that requires consideration and rectification. Such data are needed for understanding the environmental and in vivo behaviour of PFASs. They should help determine which, for which uses, and to what extent, PFASs are environmentally sustainable.

Visualization and quantification of intestinal transit and motor function by real-time tracking of 19F labeled capsules in humans

A combined (19)F and (1)H MRI framework for the assessment of human intestinal transit and motor function is presented. This framework consists of silicone coated polychlorotrifluoroethylene capsules filled with perfluoro-[15]-crown-5-ether as (19)F marker, a flexible (19)F surface coil and a (19)F projection imaging sequence, allowing for real-time tracking of a single or multiple capsules. The capsules (length 11.5 mm, Ø 7.2 mm) contain 140 μL perfluoro-[15]-crown-5-ether and were tested for cytotoxicity and leakage prior to oral administration. A balanced SSFP projection sequence was implemented, yielding a temporal resolution of 133 ms. Optional multi-frequency excitation, allowing for interleaved tracking of differently labeled (19)F capsules, was incorporated. The passage of the (19)F capsules through intestinal sections was monitored in two healthy volunteers. Capsule coordinates were successfully coregistered with anatomical reference scans. Intestinal motility, residence times, lengths and forward velocities were determined. Simultaneous tracking of two capsules allowed for the assessment of peristaltic patterns with correction for respiratory motion. By providing the means for real-time multiple capsule tracking and high resolution anatomical imaging, the presented multinuclear imaging framework has the potential to provide important supplemental information for physiological and pharmaceutical research.

3T MR of the prostate: reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension

Most prostate MRI/MRS examinations are performed with an endorectal coil inflated with air, leading to an air-tissue interface that induces magnetic susceptibility gradients within the gland. Inflation of the coil with a barium sulfate suspension is described and compared to inflation with air or liquid perfluorocarbon (PFC). The B(0) field in the prostate gland was mapped for five healthy volunteers when the endorectal coil was inflated with each of the three agents. A marked decrease in the posterior-anterior (P-A) field gradient and a significant improvement in field homogeneity were evident in the presence of a barium suspension and PFC relative to air. MRS data acquired from the prostate gland in the presence of air, PFC, and a barium suspension in the endorectal coil showed similar trends, demonstrating improvement in line-widths and spectral resolution when the barium suspension or the PFC were inflating the endorectal coil. On this basis we conclude that a barium suspension provides an available, cheap, and safe alternative to PFC, and we suggest that inflating the endorectal coil with a barium suspension should be considered for prostate MR studies, especially at high field strengths (such as 3T).

Magnetic resonance imaging evaluation of small intestinal Crohn's disease

Imaging evaluation in patients with Crohn's disease is based on morphological abnormalities, traditionally disclosed by barium studies including conventional enteroclysis, and more recently by cross-sectional imaging. A major prerequisite for optimal image quality and a more confident diagnosis is the adequate luminal distension of the bowel, which is usually achieved by administering an intraluminal contrast agent through a nasojejunal catheter. Magnetic resonance enteroclysis is a new technique that combines the advantages of volume challenge with state-of-the-art ultrafast pulse sequences, resulting in an excellent demonstration of the anatomy of the small bowel. Magnetic resonance enteroclysis compares favourably with conventional enteroclysis in detecting, localising and assessing the extent of involved small bowel segments. Luminal narrowing and extramural manifestations or complications of the disease can also be accurately assessed by the technique. Imaging features including the presence of deep ulcers, extensive wall thickening and mesenteric lymph nodes exhibiting marked gadolinium enhancement correlate strongly with disease activity. Although the clinical utility of magnetic resonance enteroclysis in Crohn's disease has been widely recognised, its routine application is currently limited to academic centres. Its clinical indications may include follow-up studies of known disease, the classification of Crohn's disease subtypes, an estimation of disease activity and a determination of the extramucosal extent and spread of the disease process.

Magnetic Resonance Enteroclysis

MR enteroclysis (MRE) is an emerging technique for the evaluation of small intestinal diseases. Administration of an iso-osmotic water solution through a nasojejunal catheter can guarantee adequate luminal distention, and in combination with ultrafast sequences, such as single shot TSE, true FISP, HASTE and 3D FLASH, results in excellent anatomic demonstration of the small intestine. MR fluoroscopy can be performed during MRE examination to monitor the filling process and might be useful in studying low-grade stenosis or motility related disorders. MRE is a very promising technique for the detection and characterization of involved small bowel segments in patients with Crohn's disease while its diagnostic performance in disclosing lumen narrowing and extramural manifestations and complications of the disease is outstanding. Initial experience shows that MRE is very efficient in the diagnosis of small bowel tumors and can be used in the evaluation of small bowel obstruction.

Cross-sectional imaging in Crohn disease

The role of cross-sectional imaging in the diagnosis of Crohn disease has expanded with recent technologic advances in computed tomography (CT) and magnetic resonance (MR) imaging that allow rapid acquisition of high-resolution images of the intestines. To acquire images of diagnostic quality, administration of a fairly large amount of intraluminal contrast agent prior to examination and scanning with intravenous contrast material injection are necessary. Both CT and MR imaging are reported to have a sensitivity of over 95% for the detection of Crohn disease; however, they may not allow early diagnosis. Colonoscopy and conventional enteroclysis studies are indicated for patients with early-stage disease. At more advanced stages, CT and MR imaging can help identify and characterize pathologically altered bowel segments as well as extraluminal lesions (eg, fistulas, abscesses, fibrofatty proliferation, increased vascularity of the vasa recta, mesenteric lymphadenopathy). These modalities can also clearly depict inflammatory lesion activity and conditions that require elective gastrointestinal surgery, thereby aiding in treatment planning. In the clinical setting, CT is currently the imaging modality of choice at most institutions; however, it is expected that MR imaging will soon play a comparable role. CT or MR imaging should be included in a comprehensive evaluation of patients with Crohn disease, along with conventional imaging and clinical and laboratory tests.

Degassed liquids to prevent/treat decompression sickness

Recompression and oxygen breathing constitute the primary treatments for decompression sickness (DCS). Increasing the volume of distribution of dissolved gas with high-volume liquid therapy represents an alternative strategy to prevent or treat DCS. Furthermore, degassing of ingested and infused liquids would increase their potential to keep supersaturated tissue gases in solution after decompression. We hypothesize that administration of degassed liquids will prevent or reverse mild-moderate DCS by increasing the volume of distribution of dissolved gas in DCS victims. Degassed perfluorocarbon ingestion offers particularly attractive potential: one liter theoretically dissolves approximately 300ml of N(2) in vivo at 1atm. One could speculate that degassed liquids may adequately treat mild DCS in lieu of recompression, particularly DCS expressed in 'fast compartment' (well-perfused) tissues. Furthermore, degassed liquid administration should prove to be even more effective adjunct therapy for severe DCS than present gas-saturated liquids.

Technical challenges and clinical applications of magnetic resonance enteroclysis

With the advent of gradient systems the image quality of ultrafast pulse sequences, i.e., half Fourier acquisition single shot turbo spin echo (HASTE), true fast imaging with steady-state processing and fast low angle shot (FLASH), improved substantially and clinical applications including small bowel imaging became feasible. Within this context, magnetic resonance enteroclysis was developed as a comprehensive examination of the small bowel, providing luminal, transmural, and exoenteric diagnostic information of small bowel abnormalities. Clinical applications of magnetic resonance enteroclysis include diagnostic evaluation and follow-up of patients with inflammatory or neoplastic diseases and small bowel obstruction.

Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population

OBJECTIVE

To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population.

MATERIALS AND METHODS

A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1-, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters, and vital signs.

RESULTS

With regard to efficacy analysis, improvement in the percent of bowel darkened was observed for 85 % of the subjects on T1-weighted images and for 95 % of the subjects on proton-density and T2-weighted images. For images of the abdominal region, the percent of bowel darkened was improved for 90-92 % of the subjects across pulse sequences. Improvement rates for the images of the pelvic region ranged from 71 % to 100 %. For at least 75 % of the subjects, proton-density and T2-weighted images of the body and tail of the pancreas, left lobe of the liver, mesenteric fat, and pathological tissue were improved relative to predosing images. Twenty-three percent of the subjects experienced some adverse effects, most of which were minor and related to the digestive system. Clinical laboratory and vital sign evaluations revealed no trends associated with the administration of perflubron.

CONCLUSION

Perflubron is a relatively safe and effective gastrointestinal MR contrast agent in the pediatric population.

A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis

The purpose of this study was to evaluate the safety and efficacy of a manganese chloride-based oral magnetic resonance (MR) contrast agent during a Phase III multisite clinical trial. Two hundred seventeen patients were enrolled who were already scheduled for MRI of the abdomen and/or pelvis. In this group of patients, it was postulated that the use of an oral agent would better allow discrimination of pathology from bowel. Patients with known gastrointestinal pathology including peptic ulcer disease, inflammatory bowel disease, obstruction, or perforation were excluded to minimize confounding variables that could affect the safety assessment. Of these 217 patients, 18 received up to 900 mL of placebo, and 199 patients were given up to 900 mL of a manganese chloride-based oral contrast agent, LumenHance (Bracco Diagnostics, Inc.). Safety was determined by comparing pre- and post-dose physical examinations, vital signs, and laboratory examinations and by documenting adverse events. Efficacy was assessed by unblinded site investigators and two blinded reviewers who compared pre- and post-dose T1- and T2-weighted MRI scans of the abdomen and/or pelvis. In 111 (57%) of the 195 cases evaluated for efficacy by site investigators (unblinded readers), MRI after LumenHance provided additional diagnostic information. Increased information was found by two blinded readers in 52% and 51% of patients, respectively. In 44/195 cases (23%) unblinded readers felt the additional information would have changed patient diagnosis and in 50 patients (26%), it would have changed management and/or therapy. Potential changes in patient diagnosis or management/therapy were seen by the two blinded readers in 8-20% of patients. No clinically significant post-dose laboratory changes were seen. Forty-eight patients (24%) receiving LumenHance and four patients (22%) receiving placebo experienced one or more adverse events. Gastrointestinal tract side effects were most common, seen in 29 (15%) of LumenHance patients and in 3 (17%) of the placebo patients. LumenHance is a safe and efficacious oral gastrointestinal contrast agent for MRI of the abdomen and pelvis.

Delivery of diagnostic agents for magnetic resonance imaging

A review of contrast agents used for magnetic resonance imaging was made with regard to methods of drug delivery using published literature. Since the clinical approval of Gd-DTPA in 1988, there has been extensive research towards developing organ- and tissue-specific contrast agents. Targeting strategies have consistently improved along with improvements in nuclear medicine imaging, and a broad spectrum of potential agents has accumulated. Liver, blood-pool targeted, and, due to their inherent convenience of delivery, intraorally administered gastrointestinal agents have been developed or are being developed. For intravenous contrast agents, collective magnetic labels with modifications for some specificities results in the larger-sized agents which can be an obstacle for the agent in accessing the targeted cells. In conclusion, the next step in the development of specific contrast agents for clinical use is to improve non-specific delivery to the extra-capillary space adjacent to targeted cells.

19F-MRI of perfluorononane as a novel contrast modality for gastrointestinal imaging

19F-Magnetic resonance imaging in conjunction with perfluorononane provides a new modality for gastrointestinal (GI) imaging as is demonstrated here with an animal model. Perfluorononane was found to be an ideal oral contrast agent since it is biologically inert, immiscible with water, and since it has a low viscosity and surface tension. Furthermore, its high fluorine content, together with the high sensitivity of 19F-MRI, allowed highly selective MR images of the GI tract of mice to be acquired. Due to the lack of 19F background signals, the contrast of the GI tract was only limited by the signal-to-noise ratio of the 19F-MR images. 19F-RARE images of 1-mm slices with an in-plane resolution of 0.23 x 0.23 mm2 were obtained from the GI tract after oral perfluorononane administration. The passage of perfluorononane through the entire GI tract was monitored by repetitive MR measurements with a maximal time resolution of 38 s. The three-dimensional surfaces of the GI tract were reconstructed and superimposed on corresponding 1H-MR images, which provided complementary anatomical information.

Highly fluorinated amphiphiles and colloidal systems, and their applications in the biomedical field. A contribution

Fluorocarbons and fluorocarbon moieties are uniquely characterized by very strong intramolecular bonds and very weak intermolecular interactions. This results in a combination of exceptional thermal, chemical and biological inertness, low surface tension, high fluidity, excellent spreading characteristics, low solubility in water, and high gas dissolving capacities, which are the basis for innovative applications in the biomedical field. Perfluoroalkyl chains are larger and more rigid than their hydrogenated counterparts. They are considerably more hydrophobic, and are lipophobic as well. A large variety of well-defined, modular fluorinated surfactants whose polar head groups consist of polyols, sugars, sugar phosphates, amino acids, amine oxides, phosphocholine, phosphatidylcholine, etc, has recently been synthesized. Fluorinated surfactants are significantly more surface active than their hydrocarbon counterparts, both in terms of effectiveness and of efficiency. Despite this, they are less hemolytic and less detergent. Fluorosurfactants appear unable to extract membrane proteins. Fluorinated chains confer to surfactants a powerful driving force for collecting and organizing at interfaces. As compared to non-fluorinated analogs, fluorosurfactants have also a much stronger capacity to self-aggregate into discrete molecular assemblies when dispersed in water and other solvents. Even very short, single-chain fluorinated amphiphiles can form highly stable, heat-sterilizable vesicles, without the need for supplementary associative interactions. Sturdy microtubules were obtained from non-chiral, non-hydrogen bonding single-chain fluorosurfactants. Fluorinated amphiphiles can be used to engineer a variety of colloidal systems and manipulate their morphology, structure and properties. Stable fluorinated films, membranes and vesicles can also be prepared from combinations of standard surfactants with fluorocarbon/hydrocarbon diblock molecules. In bilayer membranes made from fluorinated amphiphiles the fluorinated tails segregate to form an internal teflon-like hydrophobic and lipophobic film that increases the stability of the membrane and reduces its permeability. This fluorinated film can also influence the behavior of fluorinated vesicles in a biological milieu. For example, it can affect the in vivo recognition and fate of particles, or the enzymatic hydrolysis of phospholipid components. Major applications of fluorocarbons currently in advanced clinical trials include injectable emulsions for delivering oxygen to tissues at risk of hypoxia; a neat fluorocarbon for treatment of acute respiratory failure by liquid ventilation; and gaseous fluorocarbon-stabilized microbubbles for use as contrast agents for ultrasound imaging. Fluorosurfactants also allow the preparation of a range of stable direct and reverse emulsions, microemulsions, multiple emulsions, and gels, some of which may include fluorocarbon and hydrocarbon and aqueous phases simultaneously. Highly fluorinated systems have potential for the delivery of drugs, prodrugs, vaccines, genes, markers, contrast agents and other materials.

Magnetic resonance imaging of the pancreas and biliary tree

MRI of the pancreas and bile ducts is becoming more widely used due to recent advances in surface coils, breath-hold imaging techniques, and magnetic resonance cholangiopancreatography (MRCP). MRI provides a comprehensive and accurate examination for the detection, staging, and characterization of a variety of developmental, inflammatory, and neoplastic processes that involve the pancreas.

MRI of pelvic masses: efficacy of the rectal superparamagnetic contrast agent Ferumoxsil

The purpose of this study was to determine the potential value of rectally administered Ferumoxsil for pelvic MRI. Twenty patients with suspected rectosigmoid and ovarian tumors were prospectively examined before and after rectal administration of 300 to 600 ml of the superparamagnetic contrast agent Ferumoxsil. Imaging parameters (1.5-T system, phased-array coil, transverse T1-weighted spin echo (SE) and T2-weighted turbo-SE sequences, 6-mm slice thickness, 350-mm field of view [FOV], 512 x 512 matrix) were kept constant. Images were evaluated for tumor presence, lymphadenopathy, bowel involvement, and peritoneal implants. Precontrast and postcontrast studies were rated for bowel delineation, lesion/organ-to-bowel differentiation, presence of artifacts, and confidence of diagnosis. Delineation of rectum and sigmoid colon (P < .001) as well as separation of bowel and vagina, uterus/adnexa, dome of the urinary bladder, lymph nodes, and vessels improved significantly (P < .01) on both T1-weighted and T2-weighted postcontrast sequences. The rectal contrast agent did not increase the level of artifacts. Changes in diagnosis in 7 of 20 patients were mainly due to identification of colorectal tumors or bowel involvement on postcontrast images. The readers' diagnostic confidence was significantly higher on contrast-enhanced than on unenhanced studies (93 +/- 6.4% vs 68 +/- 25.2%). Rectal application of Ferumoxsil improves lesion/organ-to-bowel delineation and overall diagnostic confidence in pelvic MRI.

A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI

The purpose of this study was to assess the effectiveness and safety of Gadolite Oral Suspension as a gastrointestinal (GI) contrast agent for MRI in a phase II and two phase III multicenter clinical trials. Gadolite was administered to 306 patients with known or suspected abdominal and/or pelvic disease. MRI with T1- and T2-weighted sequences was performed before and after ingestion. Efficacy was evaluated by having two masked readers rate the certainty of their MR diagnosis (0 = uncertain, 1 = probable, 2 = definite) on randomly presented pre- and post-Gadolite Oral Suspension enhanced images. Principal investigators also evaluated the images and established the final diagnosis. Vital signs, clinical chemistries, and adverse events were documented. Blood and urine samples were analyzed for gadolinium content to determine whether Gadolite Oral Suspension was absorbed systemically. Certainty in MR diagnosis increased significantly (P < .001) for both blinded readers between pre- and post-Gadolite images (.49-1.18 for reader 1: .46-1.53 for reader 2). Sensitivity, specificity, and accuracy also increased for both masked readers. No gadolinium was detected in blood or urine samples. There were no serious adverse events and no apparent drug-related trends in mean vital signs or laboratory values. Gadolite is a highly effective, safe, and well tolerated contrast agent for clinical use with MRI.

Rectal perflubron: new application in MRI of perirectal fistulae

PURPOSE

Our goal was to determine the efficacy of MRI with rectal administration of perflubron in the evaluation of perirectal and pelvic fistulae, with an emphasis on development of an improved method for fistula visualization.

METHOD

Fourteen pelvic and/or perirectal fistulae were evaluated in nine patients with MRI after the rectal administration of 200 ml of perflubron. Images were reviewed by two independent readers and evaluated for the presence or absence of fistulae. Qualitative assessment was also performed, rating the examinations for the ability to visualize the fistulae. Comparison was made with the clinical examination and/or operative findings, as well as available preperflubron imaging studies (CT = 10; fluoroscopy = 1; preperflubron MRI = 4).

RESULTS

MRI with rectal perflubron demonstrated all 14 fistulae (100%), while preperflubron imaging demonstrated only 7 of 14 (50%) fistulae (p < or = 0.008, Wilcoxon signed rank test). In addition, MRI with perflubron resulted in significantly improved qualitative visualization of fistulae (overall very good rating versus poor rating for preperflubron imaging, p < or = 0.006, Wilcoxon signed rank test).

CONCLUSION

MRI with rectal perflubron is a superior modality for imaging of fistulae, compared with conventional methods, since it allows a noninvasive means of demonstrating the presence of a fistula as well as offers improved qualitative assessment of fistulous disease.

Ferristene as intestinal MR contrast agent. Distribution and safety of a fast ingestion procedure with oral metoclopramide

PURPOSE

To compare the small bowel distribution and safety of a fast ingestion procedure of ferristene to those of the standard ingestion procedure.

MATERIAL AND METHODS

Sixty-four patients received 0.5 g/l ferristene in 800 ml water. Thirty-four patients of the fast ingestion group ingested ferristene with 20 mg of oral metoclopramide during the course of 30 min before MR imaging and received an i.v. injection of an antiperistaltic agent during the MR study. Thirty patients of the standard group ingested ferristene during the course of 2 h, without additional drugs. Ferristene distribution was assessed by 2 reviewers and adverse events were recorded.

RESULTS

More than 50% of the small bowel segments analyzed were filled with ferristene in 30 patients in the fast ingestion group and in 28 patients in the standard ingestion group. One patient in each group experienced nausea and/or vomiting. Some bloating or sensation of fullness was reported by 2 patients in the fast ingestion group and by 3 patients in the standard ingestion group.

CONCLUSION

The distribution of ferristene in the small bowel and the safety of the procedure were thus similar in the 2 groups using either a fast ingestion procedure with oral metoclopramide or the more time-consuming standard ingestion procedure.

Oral magnetic particles (ferristene) as a contrast medium in abdominal magnetic resonance imaging

RATIONALE AND OBJECTIVES

In this phase III study, we evaluated the efficacy and safety of a negative contrast medium, ferristene (oral magnetic particles), among 277 patients undergoing magnetic resonance (MR) imaging of the abdomen.

METHODS

Enhanced (800 ml ferristene) MR images were compared with unenhanced MR images in an intraindividual-patient control design. Adverse events were recorded. The examinations were performed on 1.5-T MR systems (T1- and T2-weighted sequences).

RESULTS

Ferristene increased the diagnostic information in 50.9% of the patients, particularly in those with abdominal masses, lymphoma, or pancreatic disease. Distribution of ferristene in the stomach, duodenum, jejunum, and ileum was complete or sufficient in 70.5-85% of the studies. In 64% of the patients, we were confident in the MR findings after the use of ferristene, and ferristene disclosed additional findings in 22% of the patients. The incidence of adverse events was 9.0%, but only 3.6% of all patients experienced ferristene-related adverse events (e.g., nausea, vomiting). Most events were mild or moderate in intensity.

CONCLUSION

Ferristene was well tolerated, and for 50% of the patients it added useful diagnostic information.

Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases

The purpose of this study was to determine the tolerance and the efficacy of the oral contrast agent ferumoxsil in the assessment of gynecologic diseases. Twenty patients underwent MR imaging at 1.5 T. T1-weighted spin-echo (SE) and T2-weighted fast SE images were obtained before and after ingestion of 600-900 mL of the superparamagnetic negative contrast agent ferumoxsil. No side effects were observed. No statistically significant increase in artifact generation was present in the postcontrast images. The efficacy in bowel marking was significant for the small bowel (P = .0001) and the cecum (P < .01), but not significant in all sequences for the sigmoid. In the postcontrast images, delineation of the uterus, the right-sided adnexa, the lymph nodes, and the pathologic lesions was significantly better (P < .01), but not all sequences showed an improvement in delineation of the other pelvic organs. After administration of ferumoxsil, the level of confidence in diagnosis was significantly higher (P = .0001), but no change in diagnosis was made from the pre- to the postcontrast images. We found the oral contrast agent ferumoxsil to be well tolerated and effective in marking the bowel and in delineating the normal organs as well as the pathologic lesions on pelvic MR images.